Chemical Property of Asunaprevir
Chemical Property:
- PKA:4.49±0.40(Predicted)
- PSA：201.18000
- Density:1.37
- LogP:6.75750
- Storage Temp.:-20°C Freezer, Under inert atmosphere
- Solubility.:DMSO (Slightly), Methanol (Slightly, Heated)
- XLogP3:4.9
- Hydrogen Bond Donor Count:3
- Hydrogen Bond Acceptor Count:10
- Rotatable Bond Count:14
- Exact Mass:747.2704769
- Heavy Atom Count:51
- Complexity:1470
- Purity/Quality:
-
99%, *data from raw suppliers
Asunaprevir *data from reagent suppliers
Safty Information:
- Pictogram(s):
- Hazard Codes:
- MSDS Files:
-
SDS file from LookChem
Useful:
- Canonical SMILES:CC(C)(C)C(C(=O)N1CC(CC1C(=O)NC2(CC2C=C)C(=O)NS(=O)(=O)C3CC3)OC4=NC=C(C5=C4C=C(C=C5)Cl)OC)NC(=O)OC(C)(C)C
- Isomeric SMILES:CC(C)(C)[C@@H](C(=O)N1C[C@@H](C[C@H]1C(=O)N[C@@]2(C[C@H]2C=C)C(=O)NS(=O)(=O)C3CC3)OC4=NC=C(C5=C4C=C(C=C5)Cl)OC)NC(=O)OC(C)(C)C
- Recent ClinicalTrials:Phase III China GT 1b Interferon (IFN) Intolerant Prev Exclude Dual
- Recent EU Clinical Trials:Effect of ASV and DCV therapy on the quality of immune status in chronic HCV patients
- Recent NIPH Clinical Trials:Post-marketing, prospective and non-randomized trial regarding to daclatasvir and asunaprevir combination therapy for chronic liver disease with genotype 1 hepatitis C virus
-
Description
Sold under the trade name Sunvepra?, asunaprevir received
approval in Japan as part of a combination treatment for the hepatitis
C virus (HCV). Working in concert with daclatasvir (IX) (vide
infra), asunaprevir is a unique treatment for HCV, as it is free from both interferon and ribavirin and is administered orally. This
direct-acting anti-viral, which was developed by Bristol–Myers
Squibb (BMS), works as an NS3/4A protease inhibitor, representing
a valuable treatment option for patient populations who are
unable to receive, or do not respond to, the standard course of
treatment—peginterferon/ribavirin. Asunaprevir is an inhibitor of the hepatitis C non-structural 3/4A serine protease, which is required for viral replication. It is a direct-acting inhibitor of hepatitis C virus (HCV). It is commonly used in combination with daclatasvir and beclabuvir, which are also direct-acting HCV inhibitors.
-
Uses
Asunaprevir is an inhibitor of the viral enzyme serine protease HCV NS3. Also functions as a second generation NS3/4A protease inhibitor used in the treatment of hepatitis C.
